Report shows women affected by DCIS prefer nonsurgical treatments

When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments, according to a research letter by Zehra B. Omer, B.A., of Massachusetts General Hospital—Institute for Technology Assessment, Boston, and colleagues.

A total of 394 healthy women without a history of breast cancer participated in the study and were presented with three scenarios that described a diagnosis of DCIS as noninvasive breast cancer, breast lesion, or abnormal cells. After each scenario, the women chose among three treatment options (surgery, medication, or active surveillance).

Overall, nonsurgical options (medication and active surveillance) were more frequently selected over surgery. When DCIS was described using the term noninvasive cancer, 53 percent (208 of 394) preferred nonsurgical options, whereas 66 percent (258 of 394) preferred nonsurgical options when the term was breast lesion and 69 percent (270 of 394) preferred nonsurgical options when the term was abnormal cells. Significantly more women changed their preference from a surgical to a nonsurgical option than from a nonsurgical to a surgical option depending on terminology, according to the study results.

"We conclude that the terminology used to describe DCIS has a significant and important impact on patients' perceptions of treatment alternatives. Health care providers who use 'cancer' to describe DCIS must be particularly assiduous in ensuring that patients understand the important distinctions between DCIS and invasive cancer," the study concludes.
 

Source: 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine shows potential in preventing recurrence of triple-negative breast cancer